tldrdailynews.com logo

Novartis's Pluvicto Achieves Promising Results in Prostate Cancer Trials

1 min read
Source: Novartis
Novartis's Pluvicto Achieves Promising Results in Prostate Cancer Trials
Photo: Novartis
TL;DR

Novartis announced that its drug Pluvicto showed significant benefits in delaying disease progression in patients with PSMA-positive metastatic hormone-sensitive prostate cancer, based on interim results from the Phase III PSMAddition trial, and plans to submit for regulatory review after presenting the data.

Topics:businesshealthcare#clinical-trial#healthcare#novartis#pluvicto#prostate-cancer#radioligand-therapy
Share this article
  1. Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer  Novartis
  2. Novartis’s Cancer Treatment Pluvicto Shows Positive Results in Trial  WSJ
  3. Novartis' Pluvicto shown to slow prostate cancer in earlier setting  Yahoo Finance
  4. Novartis’ Pluvicto scores third Phase III win, this time in hormone-sensitive prostate cancer  FirstWord
  5. Novartis (NVS) Reports Positive Interim Results in Prostate Cancer Trial | NVS Stock News  GuruFocus

Want the full story? Read the original reporting

Read on Novartis